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Abstract
In a case-control study aimed at locating autosomal disease variants for a disease of
interest, association between markers and the disease status is often tested by comparing
the marker minor allele frequencies (MAFs) between cases and controls. For most com-
mon allele-based tests the statistical power is highly dependent on the actual values of these
MAFs, where associated markers with low MAFs have less power to be detected compared
to associated markers with high MAFs. Therefore, the popular strategy of selecting mark-
ers for follow-up studies based primarily on their p-values is likely to preferentially select
markers with high MAFs. We propose a new test which does not favor markers with high
MAFs and improves the power for markers with low to moderate MAFs without sacrificing
performance for markers with high MAFs and is therefore superior to most existing tests
in this regard. An explicit formula for the asymptotic power function of the proposed test
is derived theoretically, which allows for fast and easy computation of the corresponding
p-values. The performance of the proposed test is compared with several existing tests both
in the asymptotic and the finite sample size settings.
Keywords: Case-control study, efficient allele-based test, linkage disequilibrium (LD), power-
ful test, p-values, minor allele frequency (MAF)
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1 Introduction
When locating dichotomous trait loci (such as disease variants) at autosomal chromosomes, as-
sociation studies of genetic markers are typically conducted using the case-control study design.
Over the years, a fair number of genetic association tests suitable for such studies have been
proposed [1, 2]. For autosomal markers the native test would be based on genotypic informa-
tion, however, tests contrasting the observed marker allele frequencies in the samples of cases
and controls are often preferentially used due to their beneficial properties such as an ability
to reliably recover signals even under deviations from additivity of allelic effects (e.g. under a
dominance or recessive model). Among the existing tests of this type, probably the best known
example is the binomial test of equality of allele frequencies in the samples of cases and con-
trols, henceforth called the allele-based test (ABT). Other popular alternatives are the chi-square
test for association, the Fisher exact test, the logistic regression model (LRM) score test, and the
Cochran-Armitage trend test (CATT) [1, 3, 2]. The last of these has the advantage of being appli-
cable even when the assumption of Hardy-Weinberg equilibrium is violated, while the score test
stands out due to its abilities to adjust for potential confounders and to model multiple markers
(including interactions) simultaneously.
By definition, a marker is associated with a disease, or more generally with a dichotomous
trait, if it is in linkage disequilibrium (LD) with one of its causal genetic variants [2]. For most
existing tests, including those mentioned above, the power to detect a marker is highly depen-
dent on the degree of LD between the marker and the causal variant. Typically, the stronger the
LD the smaller the p-value of the test. However, the p-values also depend on the marker allele
frequencies; among markers that are in LD with the same causal variant, markers with high mi-
nor allele frequencies (MAFs) are typically much more likely to be detected than markers with
low MAFs. Consequently, the strategy of selecting individual markers for follow-up studies pri-
marily using the p-values from the existing tests is biased towards selecting markers with high
MAFs. The same holds for most alternative strategies for prioritizing markers for follow-up
studies that have been proposed in the literature such as ranking markers using the Bayes fac-
tor [4, 5], the likelihood ratio signal [6], the frequentist factor [7], or PrPES [8] as the signal
measures. A comparison between these strategies and the strategy of ranking markers using the
p-values of various allele-based tests and the CATT found that all of the considered strategies re-
sulted in highly similar ordering of markers and the markers with the smallest p-values obtained
from the ABT tended to be top-ranked by the other methods as well, and vice-versa [6]. In fact,
some of the alternative strategies exhibited a tendency to disfavor markers with small MAFs to
an even stronger degree than the ABT p-value based ranking.
In this paper we propose a novel test which can be viewed as an adjustment of the standard
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ABT for testing association in case-control studies, which reduces the preferential treatment of
markers with high MAFs. We show that the new test has equivalent or superior power compared
to the commonly used tests, and the power superiority occurs particularly in situations with low
to moderate marker MAFs. We also show how the new test can be made robust against devia-
tions from Hardy-Weinberg equilibrium, an important practical concern. We derive an explicit
formula for the test’s asymptotic power function, thus allowing for fast and easy computation of
the test’s p-values. A comparison is made with the (asymptotic) power function for the standard
ABT, the CATT, the chi-square test and the LRM score test in the absence of confounders. In
addition to the asymptotic perspective, we also investigate via simulation the power performance
of the new test in a finite sample size setting. Finally, we apply the new test to a major depression
disorder case-control data set.
2 Methods
2.1 Setting
In this paper we define causal variant, or simply variant, to mean a causal genetic locus (e.g.
SNP) and marker to mean an observed genetic locus, which may or may not be in LD with a
causal variant. For the disease of interest there may be multiple causal variants. The goal is
to identify the markers that are in LD with any of the causal variants for the given disease of
interest. For simplicity of notation, we assume that there is only one causal variant. In Section
2.7 we briefly discuss the situation with multiple causal variants.
The case-control status with respect to a given disease of interest for a random individual
from a specific population is denoted by A whenever the individual is a case (i.e. is affected
by the disease, thus also called unaffected ) and by U for a control (also called unaffected ).
Furthermore, the fraction of the cases in the total population is denoted by pi .
Suppose the causal variant is biallelic with alleles A1 and A2. Denote the corresponding
allele frequencies in the total population as p1 and p2 = 1− p1 and the frequencies of Ai only
among the controls (unaffected) and cases (affected) as pUi and p
A
i , respectively. Note that,
trivially, it holds pU1 + p
U
2 = p
A
1 + p
A
2 = 1. If a variant exhibits more than two alleles, it can still
be treated as biallelic by re-defining one of the alleles, say A2, to denote any allele that is not
A1. Further denote the fraction of the cases among the individuals with genotype (Ai,A j) at the
causal variant by pii j. Since genotypes are non-ordered, it is assumed that pi12 = pi21. Further it
is assumed that all markers are also biallelic. For a given marker, the two alleles are denoted
by M1 and M2 with q1 and q2 the corresponding frequencies in the total population. Similarly
denote the frequencies of M1 and M2 only among the controls (“unaffected”) as qU1 and q
U
2 and
only among the cases (“affected”) as qA1 and q
A
2 , respectively. Note that, again trivially, it holds
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qU1 +q
U
2 = q
A
1 +q
A
2 = 1.
In the following sections until Section 2.6 it is assumed that the marker alleles are in Hardy-
Weinberg equilibrium (HWE). In Section 2.6 we present adjustments of our test (defined in (2)
below) aimed at situations where the assumption of HWE is violated. Additionally, throughout
the paper it is assumed that genotyping errors can be neglected and that the samples of cases
and controls are random and independent selections from the cases and controls in the given
population of interest.
The total sample consists of N independent individuals of which there are R cases and S
controls, where R and S are assumed to be fixed and non-random. In other words, for biallelic
markers we observe a total of 2R and 2S alleles for the cases and the controls, respectively.
Let R0 and R1 denote the observed counts of genotypes (M1,M1) and (M1,M2) among the cases,
respectively, and let S0 and S1 denote the corresponding genotype counts among the controls. We
then estimate the frequencies of the allele M1 among the cases and the control by qˆA1 =
1
2(2R0+
R1)/R and qˆU1 =
1
2(2S0 + S1)/S, respectively. We denote the estimates of the complementary
frequencies as qˆA2 = 1− qˆA1 and qˆU2 = 1− qˆU1 .
2.2 Novel test statistic
Inspired by the binomial test of equality of allele frequencies of cases and controls (ABT) for
testing H0 : qU1 = q
A
1 versus H1 : q
U
1 6= qA1 , we propose a novel test statistic for testing H0 against
H1. We define the statistic as
Wpˆi =
√
m(qˆU1 − qˆA1 )√
qˆ1,pˆi qˆ2,pˆi
, (1)
where m = 2Nλ (1−λ ) with λ = R/N (i.e. the fraction of the cases in the sample) and
qˆi,pˆi = pˆi qˆAi +(1− pˆi)qˆUi , i = 1,2, (2)
with pˆi denoting an estimate of the disease prevalence pi . This latter estimate cannot be obtained
from the case-control data and thus additional external information is required for the estimation.
For many diseases suitable estimates of the population prevalence are readily available from
literature or other sources such as national registries (see also Section 2.4).
Assuming that pˆi is an asymptotically consistent estimator of pi , the denominator in Wpˆi
converges in probability to
√
q1q2 as the number of observations in the case-control sample and
used for estimating pi increase to infinity. Consequently, by Slutsky’s lemma and the central
limit theorem, it follows that Wpˆi is asymptotically standard normally distributed under the null
hypothesis H0. In other words, rejecting H0 whenever |Wpˆi |> ξα/2, where ξα/2 is the upper α/2-
quantile of the standard normal distribution, yields a test of H0 against H1 with an asymptotic
level of significance of α .
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Motivation
The motivation for the new statistics comes from the following equality, which we derive in
Appendix A, that reads
qU1 −qA1√
q1q2
= ∆
pU1 − pA1√
p1 p2
, (3)
where ∆ is a common measure for the degree of LD between a marker and a causal variant, de-
fined as ∆ := D11/
√
p1 p2q1q2, where Di j = P(AiM j)− piq j and P(AiM j) denotes the frequency
of the joint haplotype (Ai,M j) at the causal variant and the marker in the total population [9].
The equality (3) shows how the relative difference between the allele frequencies among the
cases and the controls at the causal variant (the quotient on the right-hand side of (3)) is passed
on to the neighboring markers through the multiplication by ∆. An immediate consequence of
(3) is this. If the marker allele frequencies among the controls and among the cases are unequal
(qU1 − qA1 6= 0), then ∆ must be non-zero, and vice versa [10, 11]. Since the goal of an asso-
ciation analysis is to find markers for which ∆ 6= 0, it follows that testing the null hypothesis
H0 : ∆ = 0 against the alternative hypothesis H1 : ∆ 6= 0 is equivalent to testing H0 : qU1 = qA1
against H1 : qU1 6= qA1 . Since typically only marker data is available, the equation (3) naturally
suggests to use a test statistic that is of the form of the left-hand side of (3). Hence the new
statistic Wpˆi .
2.3 Asymptotic power functions: A comparison
In this section we present an (asymptotic) power comparison of Wpˆi and several commonly used
tests of equality of allele frequencies as well as the classical chi-square test statistic denoted as
Tχ2 [3]. A commonly used frequency-based tests utilize the statistic T defined as
T =
√
m(qˆU1 − qˆA1 )√
λ qˆU1 qˆ
U
2 +(1−λ )qˆA1 qˆA2
.
Under the null hypothesis of no association T is asymptotically standard normally distributed.
In addition to T , two other tests of association are popularly used. Namely the Cochran-
Armitage trend test [2], for which we denote the statistic by TCATT, and the LRM score test where
the observed minor allele count is the independent variable [1]. Their powers are compared with
that of Wpˆi using a theoretical argument.
For the sake of brevity, in this paper we only focus on the additive model. However, our in-
vestigation (not shown) has indicated that the presented conclusions remain qualitatively true for
other genetic models including the dominant and the recessive models as well as other parameter
settings.
5
Power comparison between Wpˆi and T : theory
It is easy to see that the statistics T and Wpˆi are closely linked. It is straightforward to show that
Wpˆi = Qˆ−1pˆi T , where
Qˆpˆi =
√
qˆ1,pˆi qˆ2,pˆi√
λ qˆU1 qˆ
U
2 +(1−λ )qˆA1 qˆA2
.
Assuming that pˆi is asymptotically consistent and that the fraction of the cases λ is fixed, Qˆpˆi
converges in probability to Q, where Q2 = q1q2/(λqU1 q
U
2 +(1−λ )qA1 qA2 ), as m and as all of the
sample sizes underlying pˆi go to infinity. Under the alternative hypothesis it holds Q 6= 1, thus
T and Wpˆi do not have equal power. However, they do have the same level since under the null
hypothesis it holds Q = 1 (since qU1 = q
A
1 = q1). In fact, under the null hypothesis Qˆpˆi converges
in probability to 1 irrespective of the asymptotic consistency of pˆi . More specifically, if pˆi is
replaced in Qˆpˆi by any value δ ∈ (0,1), the resulting fraction Qˆδ still converges in probability to
1, meaning that for any δ ∈ (0,1) in place of pˆi the corresponding test is valid (see Section 2.4
for further discussion).
Further investigating the link between Wpˆi and T , an application of the central limit theorem
and Slutsky’s lemma yields that for m and the numbers of observations underlying pˆi all going
to infinity it holds
Wpˆi =
√
m(qˆU1 − qˆA1 )√
qˆ1,pˆi qˆ2,pˆi
=
√
m(qU1 −qA1 )√
q1q2
+Op(1) =
√
m∆(pU1 − pA1 )√
p1 p2
+Op(1),
where Op(1) denotes a term that is bounded in probability. Note that the last equality follows
from (3). Consequently, with B = (pU1 − pA1 )/
√
p1 p2, it holds that
Wpˆi =
√
m∆B+Op(1) and T =
√
m∆BQ+Op(1). (4)
In other words, for large m the power functions of the tests based on Wpˆi and T are respectively
governed by the terms
√
m∆B and
√
m∆BQ. Note that there are three types of quantities at play
here. The term
√
m is sample-specific and is the same for every marker. ∆, on the other hand,
expresses the degree of LD between the marker and the causal variant and is therefore marker-
specific, and so is the term Q. Finally, B is specific to the causal variant and is therefore the same
for all markers that are in LD with the same causal variant.
In terms of power, the asymptotic approximations in (4) show that for each marker the p-
values based on T are weighted by their sample allele frequencies via Q, where Q 6= 1 under
the alternative hypothesis. In the case of Wpˆi , however, the term Q is absent, which means
that there is no frequency-based weighing and thus the corresponding p-values are much more
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comparable over markers with different allele frequencies, especially if these markers are in LD
with the same causal variant and thus have the same value for B.
Suppose that the minor allele M1 is positively correlated with the risk allele at the variant.
Then, M1 will be enriched among the cases, and thus qU1 < q1 < q
A
1 and q
A
2 < q2 < q
U
2 . If
qA1 <
1
2 , then q
U
1 q
U
2 < q1q2 < q
A
1 q
A
2 , because the function p→ p(1− p) is concave and symmetric
around 12 . Recall that λ equals the fraction of cases. It holds Q ≤ 1 if and only if λ ≤ λ0,
with λ0 = (qA1 qA2 − q1q2)/(qA1 qA2 − qU1 qU2 ), at which point Wpˆi is more powerful than T . In most
practical situations λ = 12 (balanced design) or λ <
1
2 (more controls than cases). Although, in
practice there might be markers for which λ > λ0, this will not be common. For M1 negatively
correlated with the risk allele at the variant, the power ordering between Wpˆi and T is reversed.
However, settings with strong or even mild negative correlations between the minor allele M1
and the minor risk allele at the causal variant are not generally possible.
Power comparison of Wpˆi with T and Tχ2: numerical results
In the top row plots in Figure 1 we provide a numerical comparison of Wpˆi with T and Tχ2 in
terms of their power performances. The asymptotic power functions of Wpˆi (continuous line), T
(dashed line) and Tχ2 (dotted line) are shown as a function of q1 (left plot) and of ∆ (right plot).
The number of cases and controls was put at R = S = 10,000 and the significance level was set
to α = 5×10−8. Notice that in both plots the power functions of T and Tχ2 almost completely
overlap, which means that the two statistics have almost identical power. Moreover, the power
functions of T and Tχ2 lie fully below that of Wpˆi , which shows Wpˆi to be more powerful than
both T and Tχ2 in the considered setting. In terms of MAF, Wpˆi is the superior performer for a
majority of values. Unsurprisingly, the degree of superiority of Wpˆi weakens with increasing q1
until the ordering flips for MAF near 0.5, when the statistics T and Tχ2 both become (slightly)
more powerful than Wpˆi .
In the bottom row plots in Figure 1 the power functions for Wpˆi (continuous lines) and T
(dashed lines) are given for the same setting as before except here the design is unbalanced with
the number of cases and controls set equal to R= 6000 and S = 16,000 (left) and to R= 16,000
and S = 6000 (right). It shows the power of T to be dependent on the fraction of the cases in
the sample. Clearly, the more unbalanced in favor of the controls the design is the more the
corresponding test favors markers with large MAFs.
As discussed in the theoretical part, the power function based on Wpˆi is constant as a function
of q1, while the power functions of T and Tχ2 increase with q1. These properties drive the
behavior of these statistics for various MAFs. It explains why T and Tχ2 both favor markers
with large MAFs at the cost of those with smaller MAFs, and why Wpˆi does not exhibit such
behavior. A direct consequence of these properties is that the p-values based on Wpˆi are much
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more comparable across markers with different MAFs.
Figure 2 (right) shows the power functions for a more prevalent disease. A qualitatively
similar behavior has been observed under a number of alternative settings (results not shown).
Power comparison of Wpˆi with TCATT and the LRM score test
It has been shown that for the additive model and under the assumption of HWE, the LRM score
test (with the observed minor allele count as independent variable) is equivalent to the CATT [2].
Consequently, in this setting any test that is more powerful than the CATT is also more powerful
than the score test, and vice-versa. In other words, it is sufficient to compare the powers of the
test based on Wpˆi and the CATT test.
Under HWE, for the CATT test statistic under the additive model (TCATT(1/2)) it holds
T 2 = TCATT2(1/2)
qˆ1,pqˆ2,p
λ qˆU1 qˆ
U
2 +(1−λ )qˆA1 qˆA2
,
with qˆ1,p and qˆ2,p the pooled sample estimators for the q1 and q2 allele frequencies [2]. This in
turn yields
W 2pˆi = TCATT
2(1/2)
q1,pq2,p
q1,piq2,pi
+oP(1), (5)
with oP(1) denoting a term that converges in probability to zero. Under the null hypothesis of no
association, the fraction term in (5) equals 1, meaning that the tests based on Wpi and TCATT(1/2)
have the same asymptotic level of significance. Under the alternative hypothesis, assuming that
the minor allele M1 is positively correlated with the causal variant (i.e. the sample of cases is
enriched with carriers of the risk alleles at the causal variants) and the prevalence of cases is
higher in the pooled sample than in the population, Wpˆi is more powerful than TCATT(1/2). This
is because then the fraction term in (5) is expected to exceed one, which leads to q1,p > q1,pi and
q1,pq2,p > q1,piq2,pi . Moreover, under this setting Wpˆi is also more powerful than the LRM score
test.
Take-away message of the comparisons
The theoretical and the numerical results presented in this section show that under HWE and
for the additive model, the test based on Wpˆi is, under many relevant situations, more powerful
than the test based on T , TCATT, Tχ2 and the LRM score test. Moreover, the power functions for
Wpˆi are constant, indicating that the test does not favor markers with high MAFs, contrary to the
other test considered.
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Figure 1: Power functions for Wpˆi (continuous lines), T (dashed lines), Tχ2 (dotted line). Additive
model with p1 = 0.03,pi11 = 0.10,pi22 = 0.02, pi12 = 0.06. Top row: R = S = 10,000 (balanced
design). Bottom row left: R = 6000, S = 16,000 (unbalanced design). Bottom row right: R =
16,000, S = 6000 (unbalanced design).
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2.4 Robustness of Wpˆi against misspecification of pi
As mentioned, Wpˆi relies on an external source for an accurate estimate of the population preva-
lence pi which cannot be directly derived from the case-control data at hand. Fortunately, the
information on disease prevalence often can be acquired from literature or relevant national reg-
istries (e.g. disease prevalences in the Netherlands are published by the National Institute for
Public Health and the Environment). If no reliable estimate of pi can be obtained, a reasonable
value can be guessed by relevant experts. Nonetheless, even if good estimates are available, it is
relevant to study the robustness of the performance of Wpˆi with respect to the quality of the esti-
mate of pi . For a fixed δ ∈ (0,1) define the test statistic Wδ to be equal to Wpˆi evaluated at pˆi = δ .
Under the null hypothesis, where qU1 = q
A
1 , the denominator of Wδ converges in probability to√
q1q2 irrespective of the value of δ . Consequently, the type I error of the test based on Wpˆi is
insensitive to the quality of the prevalence estimate. However, the power of the test is dependent
on the estimate for the prevalence. In Figure 2, on the left, the asymptotic power functions of
T and Wδ=pi , Wδ=0.05, Wδ=0.1, Wδ=0.2, Wδ=0.3 as functions of q1 are plotted. The value of pi
was set at pi = 0.0224, while the other parameters were set at ∆ = 0.20, p1 = 0.03. The figure
shows that for δ equal to or near pi the power functions are more or less constant with respect
to the MAF, while for values of δ far from pi the power functions do vary with the MAF (they
increase). For values of δ < pi (underestimation of the prevalence) the power function of the test
is slightly above that for δ = pi , although the difference is small and diminishes with increasing
allele frequency q1.
In Figure 2 (right) the asymptotic power functions correspond to a setting of a more common
disease, namely p1 = 0.2, pi11 = 0.40, pi12 = 0.10, pi22 = 0.25, which yields pi = 0.16, and
R = S = 4000. The power curves are for the test-statistic Wδ with δ = 0.01, δ = 0.05, δ = 0.10,
δ = pi , δ = 0.20 (ordered top to bottom) and for T (dotted line). The plot shows a flat power
function for Wδ=pi , a slightly decreasing function for δ < pi and a slightly increasing function
for δ > pi . It also shows the robustness of the power of Wδ against minor misspecification of pi
for both overestimated and underestimated pi .
2.5 Simulation study: Type I error and power for finite samples
By their design, the p-values of the considered tests are derived using the asymptotic normality
of the underlying test statistics Wpˆi and T . In this section we study the finite sample behavior
of Wpˆi , including its robustness against departures from HWE. In an applied setting, while other
factors such as the MAF also play a role, it is the sample size that is the primary driving factor
of the accuracy of the asymptotic normal approximation underlying the p-values of the tests.
The primary goal of the simulation study is to investigate the type I error behavior in a finite
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Figure 2: Left plot: Power functions of T (dotted line) and Wδ=0.01, Wδ=pi , Wδ=0.05, Wδ=0.1,
Wδ=0.2, Wδ=0.3 (solid lines, ordered top to bottom) as a function of q1, with p1 = 0.03,pi =
0.0224, pi11 = 0.10, pi12 = 0.06, pi22 = 0.02. Right plot: Power functions of T (dotted line) and
Wδ=0.01, Wδ=0.05, Wδ=0.1, Wδ=pi , Wδ=0.2, Wδ=0.3 (solid lines, ordered top to bottom) as a function
of q1, with p1 = 0.2,pi = 0.16, pi11 = 0.40,pi12 = 0.10,pi22 = 0.25.
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sample setting for a variety of MAFs ranging between 0.03 and 0.5, which was the range of
MAFs observed in the major depression disorder data set analyzed in Section 3. In a typical
GWAS a whole range of MAFs are present, which means that an appropriate measure of the
expected type I error, and the one used in our simulation study, is the weighted average of the
observed type I errors over the entire range of MAFs with weights equal to the expected relative
representation of each MAF in the study.
For each MAF we simulated the marker alleles for R cases and for S controls with ∆ = 0
(i.e. under the null hypothesis of no association). In terms of the ratio of cases to controls
we considered two scenarios, namely the balanced design with equal numbers of cases and
controls (R = S) and an unbalanced design with the number of controls twice the number of
cases (S = 2R). We chose to focus on a setting with an excess of controls as it is typically easier
to find individuals from the control population. The selected parameter values can be seen in
Table 2.5.
Under each parameter setting we simulated 5 billion data sets and for each of them we
calculated the statistics T , Wδ=0.05, Wδ=0.1, Wδ=0.2, Wδ=0.3 and Wδ=0.4. The tests were performed
using the asymptotic standard normal approximation at the significance level α = 5× 10−8, a
value that is typically used in GWAS. The observed type I error for each statistic and each
selected MAF was calculated. Note that the number of simulated data sets (billions) had to be
very high given the low level of significance, which in turn had to be set low in order to emulate
a GWAS setting.
The overall type I error estimate was computed as a weighted average of the (estimated) type
I errors at a dense grid of MAF values with weights based on the expected relative frequencies of
each MAF. Given that in the real-life data set analyzed in Section 3 the observed distribution of
the MAFs was very close to uniform between 0.03 and 0.5, it was therefore deemed sufficient to
calculate the overall type I error as a simple (i.e. unweighted) mean of the individual simulated
error rates at the grid covering the interval from 0.03 to 0.5 (with steps of 0.005).
Type I error for finite samples
The results of the simulation studies for the type I error are presented in Table 2.5. It shows
the ratios of the observed type I errors and the significance level α for fixed values of MAF
(in all but the last column of the table). Given the small value of α , we are in fact verifying
the accuracy of the far-tail asymptotic normal approximation of the true distributions of the test
statistics. The estimates of the expected overall type I error in a GWAS are given in the last
column of the table.
The simulation results show that for T the observed type I error is slightly inflated for the
unbalanced design, while for the balanced designs the statistic performs quite well. The table
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also shows that the statistic Wpˆi exhibits a slightly inflated overall type I error, although it is worth
noting that the inflation is considerably stronger for markers with MAFs below 0.05 and small
values of δ and it steadily decreases with increasing sample size. This behavior appears to be a
consequence of the low accuracy of the normal asymptotic approximation in the far tails of the
distribution. Seeing that the results show a decreasing trend of the inflation with sample size, a
remedy would be an increase of the underlying sample size. Crucially, despite the sub-optimal
behavior of Wpˆi for the very small MAFs, it needs to be stressed that the power gains achieved
by Wpˆi relative to the commonly used tests are not solely or even primarily due to the inflated
type I error, since with growing sample size the type I error inflation vanishes while the superior
power performance remains. With R= S= 50,000 the inflation for δ = 0.05 is essentially gone.
Besides the increased sample size, an alternative remedy of the type I error inflation is to use
a larger value for δ when calculating Wδ . In other words, aim to ”overestimate” the population
prevalence of cases if pi is small. This can be an especially effective solution if used only
for markers with low MAF (e.g. below 0.1). Unsurprisingly of course, this ”overestimation”
approach does come at a price in terms of decreased power. A further alternative option is to
obtain the p-values for Wpˆi using a permutation approach. This can be done either for all markers
or only for the markers for which the type I error is expected to be inflated (typically those with
small MAF).
Power (type II error) for finite samples
Besides the type I error investigation, we also compared the power performances of the various
tests in a finite sample size setting. We simulated data under a number of parameter combinations
replicating each test 5 million times under each scenario. The significance level was again set
at 5× 10−8 and the empirical power of each test was calculated as the fraction of time the
test rejected the null at this level of significance separately for each scenario. The analysis
showed that the finite sample empirical power functions are very similar to the asymptotic power
functions (plots not shown).
2.6 Adjustments under Hardy-Weinberg Disequilibrium (HWD)
Many existing tests, including ours so far, implicitely rely on the validity of the assumption of
Hardy-Weinberg equilibrium (HWE). In applications where such assumption is expected not to
be appropriate, the usual approach is to rely on the Cochran-Armitage trend test (CATT) and its
robustness against departures from HWE. Advantageously, our newly proposed test statistic Wpˆi
as well as T can both be robustified against departures from HWE.
In [2, 12] an adjusted test statistic THWD is described. It is found by replacing the estimated
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Table 1: Type I errors divided by α = 5×10−8. The column total shows the weighted average
of type I errors over the various MAFs.
q1
0.03 0.05 0.10 0.20 0.30 0.40 0.50 total
R = S = 5000
T 0.97 1.02 1.04 1.03 1.06 1.02 0.93 1.02
Wδ=0.05 6.95 3.88 2.08 1.35 1.16 1.03 0.93 1.62
Wδ=0.10 5.41 3.17 1.84 1.24 1.16 1.00 0.93 1.47
Wδ=0.20 3.01 2.21 1.46 1.13 1.12 1.00 0.93 1.25
Wδ=0.30 1.87 1.40 1.21 1.07 1.08 0.99 0.93 1.10
Wδ=0.40 1.16 1.11 1.03 1.02 1.06 0.97 0.93 1.02
2R = S = 6000
T 2.25 1.84 1.32 1.10 1.06 0.94 0.95 1.16
Wδ=0.05 5.83 3.28 1.79 1.22 1.14 0.98 0.91 1.46
Wδ=0.10 4.24 2.58 1.60 1.16 1.07 0.98 0.90 1.32
Wδ=0.20 2.27 1.61 1.23 1.05 0.98 0.96 0.89 1.10
Wδ=0.30 1.25 1.12 1.02 1.03 0.98 0.92 0.89 0.99
Wδ=0.40 0.84 0.94 0.95 0.98 0.97 0.93 0.89 0.95
R = S = 10,000
T 0.91 0.93 1.00 1.14 0.92 1.15 1.10 1.05
Wδ=0.05 3.73 2.31 1.58 1.27 0.97 1.11 1.09 1.33
Wδ=0.10 3.02 1.99 1.43 1.20 0.96 1.12 1.08 1.25
Wδ=0.20 2.05 1.51 1.22 1.18 0.93 1.12 1.06 1.15
Wδ=0.30 1.44 1.19 1.06 1.15 0.91 1.11 1.05 1.07
Wδ=0.40 1.07 1.02 0.98 1.12 0.92 1.12 1.05 1.04
R = S = 20,000
T 1.02 1.05 0.92 1.02 1.06 1.12 1.06 1.04
Wδ=0.05 2.04 1.74 1.22 1.07 1.10 1.09 1.06 1.17
Wδ=0.10 1.79 1.58 1.14 1.05 1.09 1.09 1.06 1.14
Wδ=0.20 1.37 1.34 1.03 1.04 1.08 1.08 1.06 1.09
Wδ=0.30 1.10 1.16 0.99 1.02 1.08 1.09 1.06 1.06
Wδ=0.40 1.02 1.06 0.95 1.02 1.05 1.10 1.06 1.04
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1 q
U
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U
11− (qU1 )2
and qA1 q
A
2 +q
A
11−(qA1 )2, where qU11 and qA11 denote the frequency of the genotype (M1,M1) among
the controls and among the cases, respectively. The adjustment follows from expressions for the
variances of qˆU1 and qˆ
A
1 derived without the assumption of HWE. The unknown frequencies in
these expressions are estimated using the corresponding sample frequencies. The asymptotic
normality of the (adjusted) test statistic THWD under the null hypothesis follows by the central
limit theorem. Conveniently, the test statistic Wpˆi can be adjusted in an analogous way. To that
end we define
WHWD =
√
m(qˆU1 − qˆA1 )√
qˆ1,pˆi qˆ2,pˆi +(qˆ11,pˆi − qˆ21,pˆi)
,
where qˆ11,pˆi is an estimate of q11 defined analogously to qˆ1,pˆi of (2).
We also performed simulations that compared the performance of the adjusted test statistic
WHWD with the test TCATT(1/2) for different values of δ , to investigate the combination of both
the robustness of the test in case of a misspecified population prevalence and deviation from
HWE. The results (Appendix B) show that in the considered settings the test based on WHWD is
slightly more powerful than the CATT.
2.7 Multiple causal variants
Until this point we focused on testing for association between markers and a single causal vari-
ant. We showed that the p-values of Wpˆi can be used for identification of markers in strong LD
with the causal variant in a way that does not preferentially select markers with high MAF, a
property that is rooted in the equation (4), where the term B on the right-hand side is the same
for all considered markers. Unfortunately, the argument only applies to the situations with a
single variant, given that the term B is causal-variant specific. Since the power function and the
p-value of Wpˆi strongly depends on the value of B, only the p-values of markers that are in LD
with the same causal variant can be directly used as measures of the degree of LD with one of
the causal variants. In practice, this means that one needs to be careful when comparing p-values
of markers that are located far apart on the genome, especially if they are located on different
chromosomes. This holds for all tests mentioned in this paper. For markers that are in LD with
multiple causal variants it is in general very complicated to quantify the corresponding effect
towards the p-values of all of these tests.
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3 Application
The newly proposed test based on Wpˆi was applied to a case-control data set to identify the ge-
nomic regions that confer risk for and protection against major depressive disorder (MDD). To
this day, the efforts to identify such regions have not been very successful [13, 14]. While this
might be partially due to a lack of consensus on the exact definition of the condition (MDD) it-
self, the possibility that the disease is influenced by many genetic loci each with a small marginal
effect could be an even better explanation for the lack of success. Then, in order to detect these
loci, a more sensitive statistical test appears to be needed. We believe that our novel test statistic
might be able to at least partially answer that call.
The analyzed MDD data set was primarily collected using two databases collected in the
Netherlands [13]. The cases, i.e. the individuals affected by MDD, came primarily from the
purpose-specific Netherlands Study of Depression and Anxiety (NESDA) database, while the
controls came from the Netherlands Twin Registry (NTR), a database containing primarily data
about twin siblings and their parents. In order to achieve sufficient independence among the
controls, for each pedigree from NTR a single individual was randomly selected, thereby making
all individuals in the data set (biologically) unrelated and thus statistically independent. The total
number of cases and controls equaled 2306 and 1027, respectively. In the analysis, only markers
for which the sum of the minor allele frequency among the cases and the controls was at least
0.02 were included, resulting in a data set with over 600K markers. The population prevalence
of MDD in the relevant population is accurately estimated as pˆi = 0.15 [13], which is the value
we used in the test statistic Wpˆi .
For all markers in the database the p-values corresponding to Wpˆi and T were computed
using their asymptotic distribution. Figure 3 shows a scatter-plot of the p-values for the two test
statistics. The markers were divided into three categories based on their MAFs in the sample
of controls. The three plots show the degree of dissimilarity of the two statistics. The observed
general pattern is that for high MAF the p-values of the two tests are highly similar and with
decreasing MAF they become increasingly dissimilar.
The analysis yielded several markers with p-values below the threshold α = 5.0× 10−8.
With the exception of chromosome 15, all other chromosomes had no more than a single sig-
nificant marker. On chromosome 15 we identified 6 markers with p-values below α . These
were the markers with RS numbers rs10152733 (MAFs 0.0732 and 0.0245 among the cases and
controls, respectively), rs3784362 (0.0212/0.00734), rs1463912 (0.0249/0.00831), rs7168666
(0.0216/0.00734), rs1820416 (0.0210/0.00734), rs4777166 (0.0202/0.00642). Moreover, two
of these markers, namely rs10152733 and rs1463912, were also identified as significant by the
statistic T . Figure 6 shows a Manhattan plot of the − log(p-value) based on Wpˆi=0.15 for chro-
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Figure 3: Scatter-plots of the p-values for the test statistics T against those based on W0.15. From
left to right: qˆU1 ≤ 0.10, qˆU1 ∈ (0.10,0.25], qˆU1 ∈ (0.25,0.50].
mosome 15.
[13] contains the results of 10 GWAS studies for MDD. The data for these studies were
collected in relation to various conditions, not solely MDD. In addition to MDD, these included
recurrent MDD, alcoholism or nicotine dependence, and others. Some of the studies showed
significant association between genomic regions and MDD, however, none of these were repli-
cated by an independent study. Among the markers identified by our analysis none have been
found by one of the studies in [13]. In [14] a genome-wide association meta-analysis based in
135,458 cases and 344,901 controls was conducted. They identified 44 loci. None of these were
replicated by our analysis.
4 Discussion
Various strategies for selecting markers for follow-up studies using the case-control framework
have been proposed in the literature. As discussed in this paper, these include the allele-based
test of association which assesses the difference of marker allele frequencies between the cases
and the controls, the LRM score test, the chi-square test for association, and the Cochran-
Armitage trend test. An often observed shortcoming of the existing strategies is their preference
for markers with high MAFs at the expense of markers with low MAFs.
In this paper a novel allele-frequency-based test statistic for finding association between ge-
netic markers and a disease of interest is proposed. A competitive advantage of the statistic is
that it does not favor markers with high MAFs. In light of the known and suspected impor-
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Figure 4: Manhattan plot of the − log(p-value) based on Wpˆi=0.15 for chromosome 15.
tance of rare alleles, this means that our new test is much more suitable to be used to asses the
association of genetic markers with a disease based on the observed p-values.
An additional advantage of the new test is that the statistic can be efficiently computed using
basic summary statistics of the case-control sample. We derived the asymptotic power func-
tion of the test, which allows for efficient computation of the associated p-values, an important
strength especially compared to approaches that rely on permutation schemes in order to obtain
the p-values.
We studied the power performance of the newly proposed test and compared it with a number
of commonly used alternative tests under numerous scenarios. The obtained results were favor-
able for the new test. It was observed that compared to the existing tests the new test possesses
superior power for markers with low MAF. This behavior is unsurprising in light of the fact that
the power functions of the new tests are (nearly) constant for various marker allele frequencies,
while the power functions of the competing tests generally decline with decreasing MAF.
The calculation of the newly proposed test statistic requires the estimation of the prevalence
of the disease pi . This value cannot be directly obtained from the sampled case-control data alone
and the estimation requires external data. This, however, is not a major obstacle for the usage of
the test since for many diseases suitable estimates of population prevalence are readily available
from sources such as national registries. Furthermore, we showed that the novel statistic is fairly
robust against misspecification of the prevalence parameter, which means that even when an
accurate estimate of the prevalence is not available for the population of interest, an inaccurate
(over-)estimate (e.g. based on a related population) can be used without substantially harming
the power of the resulting test.
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Besides power, we also studied the type I error of the new test in the context of a finite
sample setting. The simulations give evidence that the type I error of the new test is inflated for
small MAFs and low prevalence pi . The specific degree of inflation depends on the underlying
sample size. However, we observed that the inflation decreases with increasing sample size and
therefore cannot be the reason for the observed power gains of the new test. Moreover, our
simulation showed that the overall type I error for the new test is expected to be only slightly
inflated in the context of a genome-wide study with a broad range of MAF values.
For many traits, only a small proportion of the variability in the population can be explained
by causal variants that have been identified so far [15]. One possible explanation for this ”miss-
ing heritability” is the presence of low-frequency variants with relatively strong effect on disease
risk. Indeed, rare variants found by re-sequencing have already been described to affect complex
diseases [16]. Given the properties of our test statistics, and in the light of the current interest
in detecting association between complex phenotypes and low-frequency variants and locating
causal variants with small minor allele frequencies [17], we believe that the novel method pre-
sented in this paper could prove to be a very useful addition to the landscape of methods available
for tackling these important problems of genetics.
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Appendix A: derivation of the equality (3)
In this section we formulate two lemmas which together constitute the proof of equality (3). We
note that throughout Appendix A (and only there) we assume that the genotypes are ordered.
For simplicity of notation, without loss of generality, we assume that the total number of causal
variants equals two.
Lemma 4.1. Let there be two causal variants and a marker of interest. Denote the genotypes
at the two causal variants as (Ai,A j) and (Bi,B j) with i, j = 1,2, respectively. Suppose that the
marker is in linkage disequilibrium with the first causal variant and in linkage equilibrium with
the second causal variant. Then,
P(MiM j|A) = qi j +D11i j pi11−pi12pi +D22i j
pi22−pi12
pi
,
P(MiM j|U) = qi j +D11i j pi12−pi111−pi +D22i j
pi12−pi22
1−pi ,
where Di jkl = P(AiA jMkMl)−P(AiA j)P(MkMl), and P(AiA jMkMl) equals the probability that
a random individual from the total population has haplotypes (Ai,Mk) and (A j,Ml). Moreover,
if HWE holds, then also Di jkl = P(AiMk)P(A jMl)− pi p jqkql .
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Proof. Write
P(MiM j|A) = ∑
k,l,m,n
P(MiM j|AkAlBmBn)P(AkAlBmBn|A)
= ∑
k,l,m,n
P(MiM j|AkAl)P(AkAlBmBn|A)
= ∑
k,l
P(MiM j|AkAl)P(AkAl|A)
= qi j +P(MiM j|A1A1) p11pi11pi +(p12P(MiM j|A1A2)+ p21P(MiM j|A2A1))
pi12
pi
+ P(MiM j|A2A2) p22pi22pi −
qi j(p11pi11+(p12+ p21)pi12+ p22pi22)
pi
= qi j +
D11i jpi11
pi
+
(D12i j +D21i j)pi12
pi
+
D22i jpi22
pi
= qi j +D11i j
pi11−pi12
pi
+D22i j
pi22−pi12
pi
,
where the last equality follows from D12i j+D21i j =−(D11i j+D22i j), since∑2,2k,l=1 Dkli j = 0. The
expression for P(MiM j|U) is found analogously. The assertion requiring HWE is trivial.
Lemma 4.2. The frequencies of the allele Mk among the cases and the controls satisfy
qAk = P(Mk|A) = qk + p1D1k
pi11−pi12
pi
− p2D1k pi22−pi12pi (6)
= qk +
√
p1 p2q1q2∆1k
(
p1
pi11−pi12
pi
− p2pi22−pi12pi
)
qUk = P(Mk|U) = qk + p1D1k
pi12−pi11
1−pi − p2D1k
pi12−pi22
1−pi
= qk +
√
p1 p2q1q2∆1k
(
p1
pi12−pi11
1−pi − p2
pi12−pi22
1−pi
)
,
where ∆ik = Dik/
√
p1 p2q1q2, Dik = P(AiMk)− piqk for i,k = 1,2, with P(AiMk) denoting the
(Ai,Mk)-haplotype frequency in the total population.
Proof. Define k¯ = 3− k. Then
qAk =
1
2
P(MkMk¯|A)+
1
2
P(Mk¯Mk|A)+P(MkMk|A)
= qk +
(1
2
D11kk¯ +
1
2
D11k¯k +D11kk
)pi11−pi12
pi
+
(1
2
D22kk¯ +
1
2
D22k¯k +D22kk
)pi22−pi12
pi
= qk + p1D1k
pi11−pi12
pi
+ p2D2k
pi22−pi12
pi
.
Since D1k =−D2k, the above expression further equals the right-hand side of (6). The expression
for qUk is found analogously.
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A crucial consequence of Lemma 4.2 is the equality
qU1 −qA1 =
√
p1 p2q1q2∆11
p1(pi12−pi11)+ p2(pi22−pi12)
pi(1−pi) .
In the case that the marker is in fact the causal variant (i.e. ∆11 = 1, p1 = q1 and p2 = q2), we
get
pU1 − pA1 = p1 p2
p1(pi12−pi11)+ p2(pi22−pi12)
pi(1−pi) .
Combining the two displays immediately yields (3)
5 Appendix B: Comparison of WHWD and TCATT(1/2)
First we focus on the type I error behavior. We simulated data under the null hypothesis of no
association with 2000 cases and 2000 controls. The MAF of the marker was again varied over
a broad range of values and the Wright’s inbreeding coefficient was alternatively set to 0.1 and
0.2. Using the significance threshold of α = 0.05, we repeated one million times the simulation
of data and hypothesis testing. The observed type I error rates were all close to α , like it should
be (results not shown).
Next, we performed simulations to compare the power of the TCATT(1/2) and WHWD statistics
under deviations of Hardy Weinberg equilibrium and misspecified population prevalence. The
allele frequency p1 was set equal to 0.03 and the Wright’s inbreeding coefficient for the causal
variant was alternatively set to 0.1 and 0.2. Given the non-zero value of ∆ (∆= 0.10), the alleles
at the marker were simulated to also be in HWD. We set R= S= 4000 and pi11 = 0.10, pi12 = 0.06
and pi22 = 0.02. The observed power functions are plotted in Figure 5, which shows a slight
power superiority of the test based on WHWD over the Cochran-Armitage test. Furthermore, the
power of the test WHWD as a function of the MAF q1 is constant, once again illustrating how
even the robustified version of the new test does not unjustly prefer markers with high MAF.
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Figure 5: Power functions for the test based on WHWD (continued lines, for δ = pi,δ = 0.05,δ =
0.20 ordered top to bottom) and TCATT(1/2) (dashed lines), for F equal to 0.1 (left plot) and 0.2
(right plot) as a function q1.
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